Received Oct 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | 2018414 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | Y013768 | — |
No additional AE; received a 3rd dose. 3rd dose was administered 10/1/2025; This spontaneous report was received from a medical assistant and refers to a(n) 11-year-old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 25-Oct-2023 when the patient was 9 years old, the patient was vaccinated with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), Suspension for injection, dose number 1, (dose, lot # and expiration date were not reported). On 04-Sep-2024, the patient was vaccinated with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) Suspension for injection (lot #2018414, expiration date: 11-Dec-2025), dose number 2.On 01-Oct-2025, the patient was vaccinated with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) Suspension for injection (lot #Y013768, expiration date: 12-Feb-2027), dose number 3 (Inappropriate schedule of product administration). All doses were administered for Prophylaxis. No adverse event was reported. Batch/Lot number is being requested and will be submitted if received.